Xin Lang Cai Jing·2026-02-02 07:16Core Viewpoint - The company, Shenzhen Hepalink Pharmaceutical Group Co., Ltd., is experiencing a decline in stock price, attributed to various market factors, including its significant overseas revenue benefiting from the depreciation of the RMB [1][3]. Group 1: Company Overview - Shenzhen Hepalink was established in 1998 and operates as a leading multinational pharmaceutical company with A+H dual financing platforms, focusing on the heparin industry chain, biopharmaceutical CDMO, and innovative drug investment, development, and commercialization [2]. - The company's main business segments include formulations (63.06%), CDMO (18.59%), heparin sodium and low molecular weight heparin raw materials (16.05%), and others (2.30%) [7]. - As of September 30, 2025, the company reported a revenue of 4.194 billion yuan, a year-on-year increase of 3.09%, while the net profit attributable to shareholders decreased by 29.04% to 554 million yuan [7]. Group 2: Financial Performance - The company's overseas revenue accounted for 93.04% of total revenue, benefiting from the depreciation of the RMB [3]. - The company has distributed a total of 4.21 billion yuan in dividends since its A-share listing, with 514 million yuan distributed over the past three years [8]. Group 3: Market Activity - On February 2, the company's stock price fell by 4.28%, with a trading volume of 80.1364 million yuan and a turnover rate of 0.53%, resulting in a total market capitalization of 17.373 billion yuan [1]. - The main capital inflow for the day was negative at 3.1333 million yuan, indicating a reduction in main capital positions over the past two days [4][5].